These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

300 related articles for article (PubMed ID: 18241919)

  • 1. Prospective evaluation of coagulopathy in multiple myeloma patients before, during and after various chemotherapeutic regimens.
    van Marion AM; Auwerda JJ; Lisman T; Sonneveld P; de Maat MP; Lokhorst HM; Leebeek FW
    Leuk Res; 2008 Jul; 32(7):1078-84. PubMed ID: 18241919
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Retrospective comparison of bortezomib-containing regimens with vincristine-doxorubicin-dexamethasone (VAD) as induction treatment prior to autologous stem cell transplantation for multiple myeloma.
    Eom HS; Min CK; Cho BS; Lee S; Lee JW; Min WS; Kim CC; Kim M; Kim Y
    Jpn J Clin Oncol; 2009 Jul; 39(7):449-55. PubMed ID: 19487425
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Cyclophosphamide plus dexamethasone is an efficient initial treatment before high-dose melphalan and autologous stem cell transplantation in patients with newly diagnosed multiple myeloma: results of a randomized comparison with vincristine, doxorubicin, and dexamethasone.
    Mellqvist UH; Lenhoff S; Johnsen HE; Hjorth M; Holmberg E; Juliusson G; Tangen JM; Westin J;
    Cancer; 2008 Jan; 112(1):129-35. PubMed ID: 17973267
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Post-transplant outcomes of induction therapy for myeloma: thalidomide and dexamethasone versus doxorubicin, vincristine, and dexamethasone prior to high-dose melphalan with autologous stem cell support.
    Vogl DT; Liu SV; Chong EA; Luger SM; Porter DL; Schuster SJ; Tsai DE; Perl A; Loren AW; Goldstein SC; Nasta SD; Andreadis C; Mangan PA; Hummel K; Siegel DL; Glatstein E; Stadtmauer EA
    Am J Hematol; 2007 Dec; 82(12):1071-5. PubMed ID: 17696204
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Complete remission status before autologous stem cell transplantation is an important prognostic factor in patients with multiple myeloma undergoing upfront single autologous transplantation.
    Kim JS; Kim K; Cheong JW; Min YH; Suh C; Kim H; Jo DY; Ryoo HM; Yoon SS; Lee JH;
    Biol Blood Marrow Transplant; 2009 Apr; 15(4):463-70. PubMed ID: 19285634
    [TBL] [Abstract][Full Text] [Related]  

  • 6. von Willebrand factor and factor VIII: C in acute cerebrovascular disease. Relationship to stroke subtype and mortality.
    Catto AJ; Carter AM; Barrett JH; Bamford J; Rice PJ; Grant PJ
    Thromb Haemost; 1997 Jun; 77(6):1104-8. PubMed ID: 9241740
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Thalidomide-dexamethasone as up-front therapy for patients with newly diagnosed multiple myeloma: thrombophilic alterations, thrombotic complications, and thromboprophylaxis with low-dose warfarin.
    Cini M; Zamagni E; Valdré L; Palareti G; Patriarca F; Tacchetti P; Legnani C; Catalano L; Masini L; Tosi P; Gozzetti A; Cavo M
    Eur J Haematol; 2010 Jun; 84(6):484-92. PubMed ID: 20192986
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A prospective study of G-CSF effects on hemostasis in allogeneic blood stem cell donors.
    LeBlanc R; Roy J; Demers C; Vu L; Cantin G
    Bone Marrow Transplant; 1999 May; 23(10):991-6. PubMed ID: 10373063
    [TBL] [Abstract][Full Text] [Related]  

  • 9. von Willebrand factor and factor VIII in renal transplant recipients under immunosuppression with cyclosporine and steroids. Sequential measurements over 4 months in 17 patients.
    Huser B; Lämmle B; Landmann J; Tran TH; Oberholzer M; Marbet GA; Thiel G; Mihatsch MJ; Duckert F
    Clin Nephrol; 1990 Nov; 34(5):214-22. PubMed ID: 2125251
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Avascular necrosis of femoral and/or humeral heads in multiple myeloma: results of a prospective study of patients treated with dexamethasone-based regimens and high-dose chemotherapy.
    Talamo G; Angtuaco E; Walker RC; Dong L; Miceli MH; Zangari M; Tricot G; Barlogie B; Anaissie E
    J Clin Oncol; 2005 Aug; 23(22):5217-23. PubMed ID: 15955903
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Impact of pretransplant therapy in patients with newly diagnosed myeloma undergoing autologous SCT.
    Kumar SK; Dingli D; Dispenzieri A; Lacy MQ; Hayman SR; Buadi FK; Rajkumar SV; Litzow MR; Gertz MA
    Bone Marrow Transplant; 2008 Jun; 41(12):1013-9. PubMed ID: 18332915
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Thalidomide in induction treatment increases the very good partial response rate before and after high-dose therapy in previously untreated multiple myeloma.
    Lokhorst HM; Schmidt-Wolf I; Sonneveld P; van der Holt B; Martin H; Barge R; Bertsch U; Schlenzka J; Bos GM; Croockewit S; Zweegman S; Breitkreutz I; Joosten P; Scheid C; van Marwijk-Kooy M; Salwender HJ; van Oers MH; Schaafsma R; Naumann R; Sinnige H; Blau I; Delforge M; de Weerdt O; Wijermans P; Wittebol S; Duersen U; Vellenga E; Goldschmidt H; ;
    Haematologica; 2008 Jan; 93(1):124-7. PubMed ID: 18166796
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Advances in therapy of multiple myeloma.
    Bladé J; Rosiñol L
    Curr Opin Oncol; 2008 Nov; 20(6):697-704. PubMed ID: 18841053
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Serum concentrations of DKK-1 decrease in patients with multiple myeloma responding to anti-myeloma treatment.
    Heider U; Kaiser M; Mieth M; Lamottke B; Rademacher J; Jakob C; Braendle E; Stover D; Sezer O
    Eur J Haematol; 2009 Jan; 82(1):31-8. PubMed ID: 19067746
    [TBL] [Abstract][Full Text] [Related]  

  • 15. High prevalence of elevated factor VIII levels in patients referred for thrombophilia screening: role of increased synthesis and relationship to the acute phase reaction.
    O'Donnell J; Tuddenham EG; Manning R; Kemball-Cook G; Johnson D; Laffan M
    Thromb Haemost; 1997 May; 77(5):825-8. PubMed ID: 9184386
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Lenalidomide in multiple myeloma.
    Thomas SK; Richards TA; Weber DM
    Best Pract Res Clin Haematol; 2007 Dec; 20(4):717-35. PubMed ID: 18070715
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Achievement of at least very good partial response is a simple and robust prognostic factor in patients with multiple myeloma treated with high-dose therapy: long-term analysis of the IFM 99-02 and 99-04 Trials.
    Harousseau JL; Avet-Loiseau H; Attal M; Charbonnel C; Garban F; Hulin C; Michallet M; Facon T; Garderet L; Marit G; Ketterer N; Lamy T; Voillat L; Guilhot F; Doyen C; Mathiot C; Moreau P
    J Clin Oncol; 2009 Dec; 27(34):5720-6. PubMed ID: 19826130
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Melphalan and dexamethasone for patients with multiple myeloma who are not candidates for autologous stem cell transplantation.
    Sharma A; Lokeshwar N; Raina V; Mohanti BK; Kumar R
    Natl Med J India; 2007; 20(3):121-4. PubMed ID: 17867615
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Consolidation therapy with low-dose thalidomide and prednisolone prolongs the survival of multiple myeloma patients undergoing a single autologous stem-cell transplantation procedure.
    Spencer A; Prince HM; Roberts AW; Prosser IW; Bradstock KF; Coyle L; Gill DS; Horvath N; Reynolds J; Kennedy N
    J Clin Oncol; 2009 Apr; 27(11):1788-93. PubMed ID: 19273705
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Combinations of cytogenetics and international scoring system can predict poor prognosis in multiple myeloma after high-dose chemotherapy and autologous stem cell transplantation.
    Inamoto Y; Kurahashi S; Imahashi N; Fukushima N; Adachi T; Kinoshita T; Tsushita K; Miyamura K; Naoe T; Sugiura I
    Am J Hematol; 2009 May; 84(5):283-6. PubMed ID: 19338045
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 15.